Outlook Therapeutics, Inc. (OTLK)
Largest Insider Buys in Sector
OTLK Stock Price History Chart
OTLK Stock Performance
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. …
Insider Activity of Outlook Therapeutics, Inc.
Over the last 12 months, insiders at Outlook Therapeutics, Inc. have bought $5.08M and sold $0 worth of Outlook Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Outlook Therapeutics, Inc. have bought $9.86M and sold $724,536 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Syntone Ventures LLC (10 percent owner) — $5M. KENYON LAWRENCE A (Chief Financial Officer) — $28,446. Evanson Jeff (CHIEF COMMERCIAL OFFICER) — $26,243.
The last purchase of 5,000 shares for transaction amount of $28,446 was made by KENYON LAWRENCE A (Chief Financial Officer) on 2024‑09‑26.
List of Insider Buy and Sell Transactions, Outlook Therapeutics, Inc.
| 2024-09-26 | Chief Financial Officer | 5,000 0.0216% | $5.69 | $28,446 | 0.00% | |||
| 2024-04-15 | 10 percent owner | 714,286 2.6874% | $7.00 | $5M | -17.00% | |||
| 2024-03-28 | director | 1,881.71 0.0143% | $11.82 | $22,242 | -39.43% | |||
| 2024-03-07 | CHIEF COMMERCIAL OFFICER | 62,484 0.0245% | $0.42 | $26,243 | -11.48% | |||
| 2023-04-20 | Sale | Chief Operations Officer | 520,000 0.2181% | $1.14 | $590,200 | -62.27% | ||
| 2023-01-20 | Sale | Chief Commercial Officer | 267,000 0.1196% | $1.11 | $296,370 | -0.92% | ||
| 2023-01-19 | Sale | Chief Commercial Officer | 103,255 0.0462% | $1.22 | $125,971 | -10.00% | ||
| 2023-01-18 | Sale | Chief Commercial Officer | 33,738 0.015% | $1.25 | $42,173 | -12.90% | ||
| 2023-01-17 | Sale | Chief Commercial Officer | 27,162 0.0122% | $1.31 | $35,582 | -15.63% | ||
| 2022-10-07 | director | 30,000 0.0135% | $1.29 | $38,700 | -9.92% | |||
| 2022-10-07 | director | 3,600 0.0016% | $1.27 | $4,572 | -9.92% | |||
| 2022-10-06 | director | 29,743 0.0134% | $1.29 | $38,368 | -9.52% | |||
| 2022-10-05 | director | 15,662 0.0068% | $1.23 | $19,264 | -8.80% | |||
| 2022-10-04 | director | 95,541 0.0427% | $1.29 | $123,248 | -10.24% | |||
| 2022-09-29 | 88,797 0.0438% | $1.24 | $110,500 | -3.36% | ||||
| 2022-06-21 | Chief Operating Officer | 10,000 0.0045% | $1.05 | $10,500 | +8.57% | |||
| 2022-06-21 | CEO and President | 19,925 0.0091% | $1.06 | $21,121 | +8.57% | |||
| 2022-03-01 | director | 27,708 0.0127% | $1.69 | $46,827 | -30.95% | |||
| 2022-02-28 | director | 6,000 0.0027% | $1.60 | $9,600 | -28.83% | |||
| 2022-02-24 | director | 41,160 0.0167% | $1.46 | $60,094 | -28.66% |
Insider Historical Profitability
| Syntone Ventures LLC | 10 percent owner | 1705438 7.2094% | $1.47 | 3 | 0 | +28.25% |
| Evanson Jeff | CHIEF COMMERCIAL OFFICER | 808459 3.4176% | $1.47 | 2 | 6 | |
| KENYON LAWRENCE A | Chief Financial Officer | 5946 0.0251% | $1.47 | 3 | 3 | +17.42% |
| Haddadin Yezan Munther | director | 5049 0.0213% | $1.47 | 6 | 0 | +52.96% |
| Sukhtian Ghiath M. | 27834257 117.6646% | $1.47 | 2 | 0 | +92.17% |
Institutional Investor Ownership
| Tang Capital Management, LLC | $19.34M | 6.92 | 1.62M | New | +$19.34M | 0.07 | |
| Great Point Partners | $17.67M | 6.32 | 1.48M | New | +$17.67M | 2.96 | |
| Armistice Capital Llc | $8.53M | 3.05 | 714,285 | New | +$8.53M | 0.03 | |
| Sphera Fund | $6.82M | 2.44 | 571,429 | New | +$6.82M | 0.04 | |
| BlackRock | $6.02M | 2.15 | 503,988 | -95.14% | -$117.76M | <0.0001 |